Aligning Evidence and Access in Oncology

João L. Carapinha, Ph.D.

Table of Contents

Poll 29 – 2026

5
Aligning Evidence and Access in Oncology

I’ve been reflecting on how oncology market access in Europe increasingly depends on stronger evidence, coordinated HTA processes, and value-based pricing. If Europe wants to improve access while sustaining innovation, what should come first? Share your insights by voting below!

 

What should be the top priority for improving oncology market access in Europe?

Table of Contents